BioSyntech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BSYI research report →
About the company
BioSyntech, Inc. is dedicated to developing advanced biotherapeutic thermogels aimed at both repairing tissues and delivering therapeutic compounds. The company's key product pipeline features BST-CarGel, a biodegradable gel designed for cartilage repair; BST-InPod, intended for alleviating heel discomfort; BST-DermOn, for managing and healing chronic wounds; BST-Ossifil, used in bone void filling; BST-Ossifix, which provides structural support for bones; and BST-Disc, focused on restoring intervertebral discs.
- CEO
- Amine Selmani
- IPO
- 2000
- HQ
- Laval, QC, CA
Price Chart
- Market Cap
- $229.03K
- P/E
- -0.00
- P/S
- 7.98
- P/B
- -0.00
- EV/EBITDA
- -0.81
- Div Yield
- 0.00%
- Gross Margin
- 60.82%
- Op Margin
- -27056.25%
- Net Margin
- -31739.11%
- ROE
- 517.27%
- ROIC
- 0.00%
- Revenue
- $40.77K · -85.12%
- Net Income
- $-12,938,767 · -39.59%
- EPS
- $-0.13 · -30.00%
- Op Income
- $-11,029,752
- FCF YoY
- -15.29%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.15
- Avg Volume
- 221
Get TickerSpark's AI analysis on BSYI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BSYI coverage
Recent articles, reports, and earnings notes.
No research on BSYI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BSYI report →Similar companies
Peers in the same neighborhood.